Biomedicines (Jan 2022)

Systemic Inflammatory Biomarkers Define Specific Clusters in Patients with Bronchiectasis: A Large-Cohort Study

  • Xuejie Wang,
  • Carmen Villa,
  • Yadira Dobarganes,
  • Casilda Olveira,
  • Rosa Girón,
  • Marta García-Clemente,
  • Luis Máiz,
  • Oriol Sibila,
  • Rafael Golpe,
  • Rosario Menéndez,
  • Juan Rodríguez-López,
  • Concepción Prados,
  • Miguel Angel Martinez-García,
  • Juan Luis Rodriguez,
  • David de la Rosa,
  • Xavier Duran,
  • Jordi Garcia-Ojalvo,
  • Esther Barreiro

DOI
https://doi.org/10.3390/biomedicines10020225
Journal volume & issue
Vol. 10, no. 2
p. 225

Abstract

Read online

Differential phenotypic characteristics using data mining approaches were defined in a large cohort of patients from the Spanish Online Bronchiectasis Registry (RIBRON). Three differential phenotypic clusters (hierarchical clustering, scikit-learn library for Python, and agglomerative methods) according to systemic biomarkers: neutrophil, eosinophil, and lymphocyte counts, C reactive protein, and hemoglobin were obtained in a patient large-cohort (n = 1092). Clusters #1–3 were named as mild, moderate, and severe on the basis of disease severity scores. Patients in cluster #3 were significantly more severe (FEV1, age, colonization, extension, dyspnea (FACED), exacerbation (EFACED), and bronchiectasis severity index (BSI) scores) than patients in clusters #1 and #2. Exacerbation and hospitalization numbers, Charlson index, and blood inflammatory markers were significantly greater in cluster #3 than in clusters #1 and #2. Chronic colonization by Pseudomonas aeruginosa and COPD prevalence were higher in cluster # 3 than in cluster #1. Airflow limitation and diffusion capacity were reduced in cluster #3 compared to clusters #1 and #2. Multivariate ordinal logistic regression analysis further confirmed these results. Similar results were obtained after excluding COPD patients. Clustering analysis offers a powerful tool to better characterize patients with bronchiectasis. These results have clinical implications in the management of the complexity and heterogeneity of bronchiectasis patients.

Keywords